Predicting the Unpredictable: What’s Missing from your Vendor Review?

Life Sciences, Pharmaceutical, Drug Discovery & Development, Preclinical,
  • Friday, February 28, 2020

There are many bioanalytical contract research organizations (CROs) that will provide quality bioanalytical services for a single project or perhaps even a single program for support of drug development. But how does a biopharma company trust to place additional projects or programs knowing they could be held hostage by the CRO to timelines and price if they place all of their eggs in one basket?

Another concern could be hearing that capacity has shifted to where they no longer have negotiated slots available or they have to set the priorities on competing resources. Contracting with another CRO could be feasible, but the current provider knows that will take too much time and energy and may even require the biopharma company to pay them not to do the work.

This webinar will demonstrate how KCAS utilizes forecasting and capacity tools to ensure clients get the results they want. Learn about different strategies to manage multiple projects seamlessly and mechanisms to help solve unpredictable issues and challenges that arise in every drug development program.


John Bucksath, CEO, KCAS Bioanalytical & Biomarker Services

John Bucksath, CEO, KCAS Bioanalytical & Biomarker Services

John Bucksath joined KCAS Bioanalytical & Biomarker Services in May of 2016 where he serves as Chief Executive Officer and Board Member. He is responsible for the overall strategic direction and future success of the organization.

Previous to joining KCAS, Mr. Bucksath worked at Analytical Bio-Chemistry (ABC) Laboratories where he served in a variety of roles from starting as a chemist and working his way to leading the organization’s technical operations starting in 2003 and eventually succeeding as President and CEO/Board member starting in 2012.    Under his leadership, ABC Laboratories and Morse Laboratories were transformed into a growing and award-winning organization as evidenced by 3 years running CRO Leadership Awards recognition by industry and double-digit growth over the period. ABC Laboratories was sold to the Evans Analytical Group (EAG) in 2015.

John serves on the Missouri Biotechnology Association’s and BioKansas’ Board of Directors. He is a member of the University of Missouri’s Research and Development Advisory Board. John is also a member of the Mizzou Venture Mentoring Program, focused on mentoring startup companies in life sciences industry. John has served as an observing Board member for two early-mid stage biotechnology companies John’s undergraduate education in Biology and Chemistry was obtained from Central Methodist University and a Masters of Business Administration from the Olin Business School – Washington University in St. Louis.

Message Presenter
Dominic Warrino, KCAS Bioanalytical and Biomarker Services

Dominic Warrino, PhD, Senior Scientific Advisor, KCAS Bioanalytical & Biomarker Services

Dominic Warrino serves as a scientific and technical advisor for both clients and internal teams for development, validation and application of bioanalytical, immunogenicity and biomarker methods for large molecule therapeutics. Dominic joined the company in 2013 and brought with him expertise in a full range of bioanalytical techniques including ECL, ELISA, RIA, flow cytometry, ELISpot, cell-based assays and Luminex. He has 20 years of experience developing and validating immunological assays for biotechnology and pharmaceutical companies. He most recently spent several years in the biopharma services department at Viracor-IBT (formally IBT), and previously also worked for Cytogen (formally Cellcor), Eligix and Streck Laboratories developing novel compounds for the treatment of various cancers. Dominic has worked on over 100 large molecule compounds developing and validating PK, PD, ADA, and biomarker assays in support of preclinical to Phase IV testing.

Message Presenter
John Perkins, KCAS Bioanalytical and Biomarker Services

John Perkins, PhD, Senior Scientific Advisor, KCAS Bioanalytical & Biomarker Services

John R. Perkins focuses on liquid chromatography/mass spectrometry (LC/MS) technologies in his role at KCAS. Previously, he was at Q2 Solutions and legacy companies for over 24 years working in quantitative LC/MS, principally with small molecules. His primary focus was on validation and sample analysis processes as well as managing customer relationships in Ithaca, NY. More recently he was responsible for the bioanalytical lab in Oss, The Netherlands.

John received his PhD in Supercritical Fluid Chromatography/Mass Spectrometry from the University of Wales, College of Cardiff, UK. He completed postdoctoral research on nanoscale separation techniques with mass spectrometry at NIEHS in Research Triangle Park. He earned his Bachelors degree in Chemistry from University of Reading, UK and a Masters degree in Advanced Analytical Chemistry from University of Bristol, UK.


Message Presenter

Who Should Attend?

This webinar will appeal to individuals working in pharma and biopharma. Specific job titles include: 

  • Directors
  • Managers
  • CEOs


What You Will Learn

Participants will learn about: 

  • How to predict if a bioanalytical CRO has the capacity to support a company’s drug development needs
  • Discuss the importance of forecasting and managing capacity at CROs
  • The processes KCAS uses to ensure capacity is available for all of types of projects

Xtalks Partner


KCAS Bioanalytical & Biomarker Services is a contract laboratory with 39+ years of bioanalytical expertise. Centrally located in Kansas City, KCAS provides small- and large-molecule PK, immunogenicity, and biomarker analysis operating a variety of equipment platforms to service a wide range of therapeutic areas. KCAS’ team leverages a highly scientific staff with an average tenure in the field of bioanalysis/biomarker analysis of 22 years to provide clients of all sizes with expertise in robust assay development, validation, and sample analysis under fit-for-purpose Non-GLP, GLP, and GCP conditions for discovery, preclinical and clinical studies. Our teams have developed and validated more than 5,500 bioanalytical assays and have undergone 16 FDA inspections.

You Must Login To Register for this Free Webinar

Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.

Create Account